Remy R. Coeytaux, MD, PhD; John W. Williams Jr., MD, MHS; Rebecca N. Gray, DPhil; Andrew Wang, MD
Surgical aortic valve replacement (SAVR) is the only treatment known to improve symptoms and survival in patients with severe, symptomatic aortic stenosis. Perioperative mortality, however, is high among many patients for whom SAVR may be indicated. Percutaneous heart valve replacement (PHVR) is an emerging, catheter-based technology that allows for implantation of a prosthetic valve without open heart surgery.
This review describes the available literature on PHVR for aortic stenosis, which comprised 84 published reports representing 76 distinct studies and 2375 unique patients. Successful implantation was achieved in 94% of patients; 30-day survival was 89%. Differences between patients undergoing PHVR and those typically selected for SAVR make full interpretation of these results difficult.
A large, multicenter, randomized, controlled trial comparing PHVR with SAVR or medical management was recently completed, with initial results expected in September 2010. Pending publication of findings from that trial, the available evidence is inadequate to determine the most appropriate clinical role of PHVR or the specific patient populations for whom it might eventually be indicated.
Left. Edwards SAPIEN transcatheter heart valve (Edwards Lifesciences, Irvine, California). Right. Medtronic CoreValve ReValving aortic bioprosthesis (Medtronic, Minneapolis, Minnesota).
Coeytaux RR, Williams JW, Gray RN, et al. Percutaneous Heart Valve Replacement for Aortic Stenosis: State of the Evidence. Ann Intern Med. 2010;153:314–324. doi: https://doi.org/10.7326/0003-4819-153-5-201009070-00267
Download citation file:
Published: Ann Intern Med. 2010;153(5):314-324.
Cardiology, Valvular Heart Disease.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use